Suppr超能文献

在肠道病毒D68相关麻痹性脊髓炎小鼠模型中评估治疗效果

Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis.

作者信息

Hixon Alison M, Clarke Penny, Tyler Kenneth L

机构信息

Medical Scientist Training Program.

Neuroscience Program.

出版信息

J Infect Dis. 2017 Dec 5;216(10):1245-1253. doi: 10.1093/infdis/jix468.

Abstract

BACKGROUND

Enterovirus D68 (EV-D68)-associated acute flaccid myelitis (AFM) is a devastating neurological disease for which there are no treatments of proven efficacy. The unpredictable temporal and geographic distribution of cases and the rarity of the disease make it unlikely that data from randomized controlled trials will be available to guide therapeutic decisions. We evaluated the following 3 widely used empirical therapies for the ability to reduce the severity of paralysis in a mouse model of EV-D68 infection: (1) human intravenous immunoglobulin (hIVIG), (2) fluoxetine, and (3) dexamethasone.

METHODS

Neonatal mice were injected intramuscularly with a human 2014 EV-D68 isolate that reliably induces paralysis in mice due to infection and loss of spinal cord motor neurons. Mice receiving treatments were evaluated for motor impairment, mortality, and spinal cord viral load.

RESULTS

hIVIG, which contained neutralizing antibodies to EV-D68, reduced paralysis in infected mice and decreased spinal cord viral loads. Fluoxetine had no effect on motor impairment or viral loads. Dexamethasone treatment worsened motor impairment, increased mortality, and increased viral loads.

CONCLUSION

Results in this model of EV-D68-associated AFM provide a rational basis for selecting empirical therapy in humans and establish this model as a useful system for evaluating other potential therapies.

摘要

背景

肠道病毒D68(EV-D68)相关急性弛缓性脊髓炎(AFM)是一种严重的神经系统疾病,目前尚无经证实有效的治疗方法。病例的时间和地理分布不可预测,且该疾病罕见,因此不太可能获得来自随机对照试验的数据来指导治疗决策。我们评估了以下3种广泛使用的经验性疗法在EV-D68感染小鼠模型中减轻瘫痪严重程度的能力:(1)人静脉注射免疫球蛋白(hIVIG),(2)氟西汀,以及(3)地塞米松。

方法

给新生小鼠肌肉注射一株2014年的人源EV-D68分离株,该分离株因感染和脊髓运动神经元丧失而能可靠地诱导小鼠瘫痪。对接受治疗的小鼠进行运动功能障碍、死亡率和脊髓病毒载量评估。

结果

含有针对EV-D68的中和抗体的hIVIG减轻了感染小鼠的瘫痪程度,并降低了脊髓病毒载量。氟西汀对运动功能障碍或病毒载量没有影响。地塞米松治疗使运动功能障碍恶化,增加了死亡率,并增加了病毒载量。

结论

该EV-D68相关AFM模型的结果为选择人类经验性治疗提供了合理依据,并将该模型确立为评估其他潜在疗法的有用系统。

相似文献

1
Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis.
J Infect Dis. 2017 Dec 5;216(10):1245-1253. doi: 10.1093/infdis/jix468.
2
A mouse model of paralytic myelitis caused by enterovirus D68.
PLoS Pathog. 2017 Feb 23;13(2):e1006199. doi: 10.1371/journal.ppat.1006199. eCollection 2017 Feb.
3
A neonatal mouse model of Enterovirus D68 infection induces both interstitial pneumonia and acute flaccid myelitis.
Antiviral Res. 2019 Jan;161:108-115. doi: 10.1016/j.antiviral.2018.11.013. Epub 2018 Nov 29.
4
VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis.
J Virol. 2024 Jul 23;98(7):e0039724. doi: 10.1128/jvi.00397-24. Epub 2024 Jun 13.
7
Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis.
J Virol. 2023 May 31;97(5):e0015623. doi: 10.1128/jvi.00156-23. Epub 2023 May 8.

引用本文的文献

1
Elucidating the role of human skeletal muscles in the pathogenesis of enterovirus D68 infection.
Life Sci Alliance. 2025 Sep 5;8(11). doi: 10.26508/lsa.202503372. Print 2025 Nov.
2
EV-D68 neurological disease: tipping the scales toward immunopathogenesis.
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI195839.
3
A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis.
Nat Commun. 2025 Jul 1;16(1):5987. doi: 10.1038/s41467-025-61083-8.
4
Advances in the Treatment of Enterovirus-D68 and Rhinovirus Respiratory Infections.
Infect Dis Rep. 2025 Jun 1;17(3):61. doi: 10.3390/idr17030061.
5
Immune cells promote paralytic disease in mice infected with enterovirus D68.
J Clin Invest. 2025 Jun 3;135(15). doi: 10.1172/JCI188495. eCollection 2025 Aug 1.
7
Insights Into Enterovirus D68 Immunology: Unraveling the Mysteries of Host-Pathogen Interactions.
Immun Inflamm Dis. 2025 Feb;13(2):e70117. doi: 10.1002/iid3.70117.
8
Emerging Therapeutics in the Fight Against EV-D68: A Review of Current Strategies.
Influenza Other Respir Viruses. 2024 Dec;18(12):e70064. doi: 10.1111/irv.70064.
10
Adult Onset Acute Flaccid Myelitis: A Case Report.
Cureus. 2024 Jul 24;16(7):e65294. doi: 10.7759/cureus.65294. eCollection 2024 Jul.

本文引用的文献

1
Unusual increase of cases of myelitis in a pediatric hospital in Argentina.
Arch Argent Pediatr. 2017 Aug 1;115(4):364-369. doi: 10.5546/aap.2017.eng.364.
2
First Cases of Severe Flaccid Paralysis Associated With Enterovirus D68 Infection in Spain, 2015-2016.
Pediatr Infect Dis J. 2017 Dec;36(12):1214-1216. doi: 10.1097/INF.0000000000001668.
3
Acute segmental poliomyelitis-like flaccid paralysis in an adult in the UK, associated with enterovirus D68.
Pract Neurol. 2017 Aug;17(4):297-301. doi: 10.1136/practneurol-2017-001609. Epub 2017 Jun 16.
4
Outcomes of Colorado children with acute flaccid myelitis at 1 year.
Neurology. 2017 Jul 11;89(2):129-137. doi: 10.1212/WNL.0000000000004081. Epub 2017 Jun 14.
5
Surveillance for enterovirus D68 in colorado children reveals continued circulation.
J Clin Virol. 2017 Jul;92:39-41. doi: 10.1016/j.jcv.2017.05.009. Epub 2017 May 11.
8
Pediatric Acute Flaccid Paralysis: Enterovirus D68-Associated Anterior Myelitis.
J Emerg Med. 2017 Jul;53(1):e19-e23. doi: 10.1016/j.jemermed.2017.03.020. Epub 2017 Apr 12.
9
The emergence of enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus respiratory screening.
Epidemiol Infect. 2017 Jul;145(9):1855-1864. doi: 10.1017/S0950268817000590. Epub 2017 Apr 3.
10
A mouse model of paralytic myelitis caused by enterovirus D68.
PLoS Pathog. 2017 Feb 23;13(2):e1006199. doi: 10.1371/journal.ppat.1006199. eCollection 2017 Feb.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验